Cj. Faherty et al., THE FUNCTIONAL SENSITIZATION OF SIGMA-RECEPTORS FOLLOWING CHRONIC SELECTIVE SEROTONIN REUPTAKE INHIBITOR TREATMENT, European journal of pharmacology, 346(1), 1998, pp. 15-21
The purpose of the present study was to investigate the potential impa
irment of normal motor function following chronic selective serotonin
reuptake inhibitor treatment that may result from sensitisation of sig
ma receptors. Rats were chronically treated with either sertraline, ci
talopram, paroxetine or fluvoxamine and a selective sigma receptor lig
and, di-o-tolylguanidine (DTG), for 28 days. All animals then received
an acute intra-rubral injection of either DTG or saline. Following th
e direct injection of DTG into the red nucleus, rats chronically treat
ed with DTG exhibit a maximal behavioural response characterised as a
pronounced dystonia. Animals chronically treated with sertraline and c
italopram elicited a response similar to that of control animals follo
wing the acute DTG challenge, whereas chronic treatment with paroxetin
e and fluvoxamine significantly decreased and increased the dystonic r
esponse, respectively. Facial spasticity and vacuous chewing movements
were associated with, and reflected the extent of, the DTG-induced dy
stonia. Changes in regional biogenic amine concentrations were also de
termined. The concentrations of serotonin and noradrenaline were deter
mined in the brain stem and cerebellum following the intra-rubral inje
ction of either saline or DTG in animals that had been chronically tre
ated with a selective serotonin reuptake inhibitor or DTG. There was a
significant increase in serotonin concentration in the brain stem as
a result of chronic DTG and fluvoxamine treatments. The increase in se
rotonin correlated with the reported potentiation of dystonia in anima
ls that received 28 days treatment with these drugs. The potentiation
of dystonia following chronic DTG and fluvoxamine treatments suggests
that these drugs sensitise the sigma(2) receptors, an effect that does
not appear to be shared by citalopram, sertraline or paroxetine. (C)
1998 Elsevier Science B.V.